Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
China and Uruguay Strengthen Strategic Partnership Amid Shifting Global Order 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Starmer’s China Visit Highlights Western Balancing Act Amid U.S.-China Rivalry 
Gold and Asian Stocks Rebound as Market Volatility Eases and Global Sentiment Improves 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
U.S. Stock Futures Slip as Markets Brace for Big Tech Earnings and Key Data 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Indian Rupee Strengthens Sharply After U.S.-India Trade Deal Announcement 
Philippines Manufacturing PMI Hits Nine-Month High Despite Weak Confidence Outlook 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Dollar Holds Firm as Strong U.S. Data, Fed Expectations and Global Central Bank Moves Shape Markets 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Moderna Inc. enters a historic $1 billion deal with China to research, develop, and produce exclusive mRNA medicines in the country. The agreement, announced amid growing Sino-American tensions, signifies Beijing's increasing openness to foreign pharmaceutical involvement.
The Cambridge, Massachusetts-based pharmaceutical and biotechnology company announced the new deal with Chinese officials on Wednesday, July 5. The agreement is for Moderna to research, develop and produce messenger RNA medicines in the country.
CNBC noted that an agreement was reached despite the growing tensions between China and the United States. Moderna and Beijing signed a memorandum of understanding (MOU) and land collaboration deal to develop drugs that will be made "exclusively for the Chinese people." This means the two sides agreed that the new drug would never be exported and remain in China.
A local media publication reported earlier this week that Moderna is set to invest about $1 billion in the project. It was added that Moderna's chief executive officer, Stephane Bancel, is set to visit Shanghai, possibly to talk more about the deal and for facility inspection.
"These agreements are focused on strengthening health security by targeting unmet needs and contributing to the ecosystem of medical solutions available to patients in China," the company's spokesman stated.
In a separate statement that was sent to Yahoo Finance, Moderna said, "We signed a memorandum of understanding and a related land collaboration agreement to work toward opportunities for Moderna to research, develop and manufacture mRNA medicines in China."
The deal shows that Moderna is trying to take advantage of the success of its COVID-19 vaccine that has been used on people worldwide. The vaccine used a platform called mRNA to push human cells to make an immune response against a virus. At any rate, the agreement was sealed on Wednesday, and this is Moderna's very first deal with the Chinese government.
Photo by: Ian Hutchinson/Unsplash
